Integra LifeSciences Holdings Corporation (IART)Healthcare | Medical Devices | Princeton, United States | NasdaqGS
18.58 USD
-0.21
(-1.118%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:59 a.m. EDT
The investment case for Integra LifeSciences is currently broken by a severe structural deterioration in its business trajectory. The stock has suffered a catastrophic 68.7% decline over the last nine years, driven by four consecutive years of negative annual returns, including a staggering 58.8% drop last year. This multi-year decline is not a temporary market correction; it reflects a fundamental failure of the business to generate value, evidenced by negative earnings per share (-$6.47), negative return on equity (-38.6%), and a lack of sustainable profitability. While the forward P/E appears cheap at 7.2x, this is a value trap resulting from the market correctly pricing in the company's inability to execute and grow. The absence of any dividend payments eliminates income as a buffer against this risk. Options activity confirms this pessimism, with traders aggressively buying deep out-of-the-money puts while showing almost no interest in upside potential. Despite recent news of management changes and a raised profit outlook, the historical data suggests these are insufficient to reverse a decade-long trend of destruction. The stock remains a high-risk speculative vehicle with no clear path to recovery. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.371149 |
| AutoARIMA | 0.372803 |
| AutoETS | 0.372803 |
| AutoTheta | 0.400314 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 4.86 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.002 |
| Excess Kurtosis | 0.90 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 195.785 |
| Revenue per Share | 21.415 |
| Market Cap | 1,445,466,496 |
| Forward P/E | 7.10 |
| Beta | 1.22 |
| Profit Margins | -30.15% |
| Website | https://www.integralife.com |
As of July 11, 2026, 5:59 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts (strikes $7.50 and $12.50) expiring in September and December. Conversely, call activity is concentrated in deep out-of-the-money strikes ($22.50) with very low volume, indicating a lack of bullish conviction. Implied volatility is significantly elevated for puts compared to calls, suggesting the market prices in a high probability of further decline rather than a rebound.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5389025 |
| Address1 | 1,100 Campus Road |
| All Time High | 77.4 |
| All Time Low | 1.356239 |
| Ask | 23.44 |
| Ask Size | 2 |
| Audit Risk | 1 |
| Average Analyst Rating | 2.7 - Hold |
| Average Daily Volume10 Day | 1,015,060 |
| Average Daily Volume3 Month | 1,028,737 |
| Average Volume | 1,028,737 |
| Average Volume10Days | 1,015,060 |
| Beta | 1.218 |
| Bid | 13.32 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 13.395 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 18.58 |
| Current Ratio | 3.379 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 18.91 |
| Day Low | 18.185 |
| Debt To Equity | 195.785 |
| Display Name | Integra LifeSciences |
| Earnings Call Timestamp End | 1,777,984,200 |
| Earnings Call Timestamp Start | 1,777,984,200 |
| Earnings Timestamp | 1,777,984,200 |
| Earnings Timestamp End | 1,785,414,600 |
| Earnings Timestamp Start | 1,785,414,600 |
| Ebitda | 308,296,992 |
| Ebitda Margins | 0.18747 |
| Enterprise To Ebitda | 10.447 |
| Enterprise To Revenue | 1.959 |
| Enterprise Value | 3,220,843,520 |
| Eps Current Year | 2.44978 |
| Eps Forward | 2.61783 |
| Eps Trailing Twelve Months | -6.47 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 609 750 4277 |
| Fifty Day Average | 15.9396 |
| Fifty Day Average Change | 2.6404 |
| Fifty Day Average Change Percent | 0.16565032 |
| Fifty Two Week Change Percent | 53.89025 |
| Fifty Two Week High | 18.92 |
| Fifty Two Week High Change | -0.34000015 |
| Fifty Two Week High Change Percent | -0.01797041 |
| Fifty Two Week Low | 8.7 |
| Fifty Two Week Low Change | 9.88 |
| Fifty Two Week Low Change Percent | 1.1356323 |
| Fifty Two Week Range | 8.7 - 18.92 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 808,579,800,000 |
| Float Shares | 58,696,207 |
| Forward Eps | 2.61783 |
| Forward P E | 7.0974813 |
| Free Cashflow | 69,289,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 4,427 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.56716 |
| Gross Profits | 932,694,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14293 |
| Held Percent Institutions | 1.00177 |
| Implied Shares Outstanding | 77,796,903 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,483,488,000 |
| Last Split Factor | 2:1 |
| Long Business Summary | Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. |
| Long Name | Integra LifeSciences Holdings Corporation |
| Market | us_market |
| Market Cap | 1,445,466,496 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_30012 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -495,798,016 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,461,803,807 |
| Number Of Analyst Opinions | 8 |
| Open | 18.39 |
| Operating Cashflow | 71,444,000 |
| Operating Margins | 0.10406999 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.67 |
| Phone | 609 275 0500 |
| Previous Close | 18.79 |
| Price Eps Current Year | 7.5843544 |
| Price Hint | 2 |
| Price To Book | 1.3870847 |
| Price To Sales Trailing12 Months | 0.8789649 |
| Profit Margins | -0.30149 |
| Quick Ratio | 1.528 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.72727 |
| Region | US |
| Regular Market Change | -0.210001 |
| Regular Market Change Percent | -1.11762 |
| Regular Market Day High | 18.91 |
| Regular Market Day Low | 18.185 |
| Regular Market Day Range | 18.185 - 18.91 |
| Regular Market Open | 18.39 |
| Regular Market Previous Close | 18.79 |
| Regular Market Price | 18.58 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 787,692 |
| Return On Assets | 0.02543 |
| Return On Equity | -0.38634998 |
| Revenue Growth | 0.024 |
| Revenue Per Share | 21.415 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 77,796,903 |
| Shares Percent Shares Out | 0.082200006 |
| Shares Short | 6,394,225 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 7,985,286 |
| Short Name | Integra LifeSciences Holdings C |
| Short Percent Of Float | 0.113299996 |
| Short Ratio | 6.52 |
| Source Interval | 15 |
| State | NJ |
| Symbol | IART |
| Target High Price | 27.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 18.0 |
| Target Median Price | 17.0 |
| Total Cash | 265,502,000 |
| Total Cash Per Share | 3.413 |
| Total Debt | 2,040,878,976 |
| Total Revenue | 1,644,509,952 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.47 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.9797 |
| Two Hundred Day Average Change | 5.6003 |
| Two Hundred Day Average Change Percent | 0.43146604 |
| Type Disp | Equity |
| Volume | 787,692 |
| Website | https://www.integralife.com |
| Zip | 8,540 |